Human Microbiome Market worth $1,598 million by 2028

Posted March 30, 2022 by mmvaidya

The human microbiome market's size was estimated through various secondary research approaches and triangulated with inputs from primary research.
According to the new market research report, "Human Microbiome Market by Product (Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application (Therapeutic, Diagnostic), Disease (Infectious, Metabolic/Endocrine), Research Technology (Genomics, Proteomics, Metabolomics) - Global Forecast to 2028" The human microbiome market is projected to reach USD 1,598 million by 2028 from USD 894 million in 2025, at a CAGR of 21.3% from 2025 to 2028.

Download PDF Brochure@

Global Industry Growth Boosting Factors:

Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is also expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market's growth.


This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global human microbiome market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The human microbiome market's size was estimated through various secondary research approaches and triangulated with inputs from primary research.

Driver: Increasing focus on human microbiome therapeutics development

Human gut microbiomes play a major role in improving the efficacy of therapeutic compounds. Over the years, studies have shown that the right combination of microbes in the human body is beneficial for treating different conditions. This association between microbes and specific disease states could generate new opportunities for drug developers (or vaccine manufacturers). Microbes are rich sources of enzymes, owing to which they can be used in various therapeutic applications, such as the search for novel therapies.

Request Sample Pages@

Opportunity: Increasing collaborations between public-private organizations

With several small innovative players operating in the market, there are various high-growth opportunities for key stakeholders to buy out companies so as to study microbiomes in the hope of identifying new drugs and drug targets for various indications, such as obesity, liver disorders, diabetes, and metabolic disorders. Many market leaders are focusing on strategic collaborations and partnerships to increase their product pipelines with well-organized research and development techniques. In the last two years, there have been several collaborations and partnerships involving major companies.

Challenge: Lack of expertise and inadequate research

The concept of bio-ecologic control of the gut has recently been proposed as a novel method of improving human health. This approach involves the use of probiotics and prebiotics. However, the mechanisms by which prebiotic bio-ecologic strategies exert their beneficial health effects remain largely unknown. It is also unknown how bacteria interact with each other or with the human body to cause or prevent certain diseases. Considering the large variability in the human intestinal ecosystem, these approaches are unlikely to fulfill their potential until the exact profile of an individual’s microbiome can be determined. Collecting, sequencing, and analyzing DNA from thousands of microbial species living in and on humans requires an interdisciplinary team with the knowledge of clinical ethics, engineering, and bioinformatics.

Restraints: Barriers in proving the causal link between dysbiosis and diseases

The human body is home to a diverse community of symbiotic, commensal, and pathogenic microorganisms, collectively known as the microbiota. Various studies also suggested that that only 30-40 species as the bulk of microbiota are shared among individuals. Analyzing specific bacteria from among trillions of species can be a highly challenging task. High-throughput omics technologies can identify the exact bacterial species involved and provide an understanding of how homeostasis between humans and microbes is maintained. According to human microbiome research, dysbiosis of microbiomes results in some of the most chronic and lifestyle diseases, such as obesity, diabetes, and various digestive disorders.

Speak to Analyst for More Detailed Information@
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Makarand Vaidya
Country United States
Categories Industry , Medical , News
Tags human microbiome , human microbiome market
Last Updated March 30, 2022